Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

ENDRA Life Sciences (NDRA) Amortization of Deferred Charges (2016)

ENDRA Life Sciences has reported Amortization of Deferred Charges over the past 1 years, most recently at $338164.0 for Q4 2016.

Quarterly Amortization of Deferred Charges changed N/A to $338164.0 in Q4 2016 from the year-ago period, while the trailing twelve-month figure was $684283.0 through Dec 2017, changed N/A year-over-year, with the annual reading at $232426.0 for FY2020, 90.13% down from the prior year.
Amortization of Deferred Charges was $338164.0 for Q4 2016 at ENDRA Life Sciences, down from $346119.0 in the prior quarter.
Over five years, Amortization of Deferred Charges peaked at $346119.0 in Q3 2016 and troughed at $338164.0 in Q4 2016.